The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors.
Eric Steven Engelman
No relevant relationships to disclose
Roberto Leon-Ferre
No relevant relationships to disclose
Boris G. Naraev
No relevant relationships to disclose
Nancy Sharma
No relevant relationships to disclose
Anna M Button
No relevant relationships to disclose
Gideon Zamba
No relevant relationships to disclose
Shiliang Sun
No relevant relationships to disclose
Thomas M. O'Dorisio
No relevant relationships to disclose
Thorvardur Ragnar Halfdanarson
No relevant relationships to disclose